AUTO3, the first chimeric antigen receptor (CAR) T‐cell therapy targeting both CD19 and CD22, shows promise in combination with pembrolizumab in patients with relapsed/refractory diffuse large B‐cell ...lymphoma, according to results from a phase I trial.
In an update from the ongoing phase II ZUMA‐5 trial, axicabtagene ciloleucel showed a high response rate and durable clinical benefit in patients with relapsed/refractory indolent non‐Hodgkin ...lymphoma, including follicular lymphoma and marginal zone lymphoma.
In the phase III KEYNOTE‐204 trial, pembrolizumab significantly improved progression‐free survival compared with brentuximab vedotin in patients with relapsed or refractory classic Hodgkin lymphoma ...(cHL), confirming pembrolizumab as the new standard of care in this setting.
In the phase I ALPHA trial, the first allogeneic “off‐the‐shelf” CAR T‐cell therapy regimen showed clinical benefits in patients with relapsed/refractory large B‐cell or follicular lymphoma.
In the era of chimeric antigen receptor (CAR) T‐cell therapy for relapsed/refractory diffuse large B‐cell lymphoma (DLBCL), a new analysis from the Center for International Blood & Marrow Transplant ...Research (CIBMTR) confirms an ongoing role for autologous transplant in patients with chemosensitive relapsed DLBCL.
Zanubrutinib, obinutuzumab, and venetoclax (BOVen), given on a treatment schedule driven by minimal residual disease milestones, is a promising approach to previously untreated chronic lymphocytic ...leukemia, according to new findings from an investigator‐initiated phase II study.
Adding venetoclax to standard chemoimmunotherapy with R‐EPOCH showed promising antitumor activity in two lymphoma trials: a phase II trial of patients with previously untreated or relapsed/refractory ...Richter's syndrome and a phase I trial of patients with previously untreated aggressive B‐cell lymphoma.
The New Normal of Our Conferences MOCHIYAMA, Hiromi
Journal of The Society of Instrument and Control Engineers,
2021/09/10, Volume:
60, Issue:
9
Journal Article
Aktuelle Debatten über künstliche Intelligenz verbinden häufig die Realitäten von KI-Technologien mit den fiktiven Darstellungen dessen, was sie eines Tages werden könnten. Sie sollen in der Lage ...sein, viel schneller zu lernen, autonome Entscheidungen zu treffen oder Informationen zu verarbeiten als Menschen, was Hoffnungen und Ängste gleichermaßen weckt. Was ist, wenn diese nützlichen Technologien eines Tages ihre eigenen Absichten entwickeln, die denen des Menschen zuwiderlaufen?
PDF
